1 / 23

Diagnosis and management of tuberculosis, and measures for its prevention and control

Diagnosis and management of tuberculosis, and measures for its prevention and control. Implementing NICE guidance. 2 nd edition May 2012. NICE clinical guideline 117. Updated guidance.

rupali
Télécharger la présentation

Diagnosis and management of tuberculosis, and measures for its prevention and control

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diagnosis and management of tuberculosis, and measures for its prevention and control Implementing NICE guidance 2nd edition May 2012 NICE clinical guideline 117

  2. Updated guidance • This guideline updates and replaces ‘Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control’ NICE clinical guideline (2006).New recommendations, 1.1.1.1 to 1.1.1.18, on using interferon gamma tests (IGTs) for the diagnosis of latent tuberculosis (TB), have been added. • 11 other recommendations have been amended.

  3. What this presentation covers • Scope • Background and definitions • Epidemiology • Key priorities for implementation • New 2011 recommendations • Costs and savings • Discussion • NICE PH37: TB among hard-to-reach groupsNICE Pathway, NHS Evidence and Find out more

  4. Scope • The update covered: • the diagnosis of latent TB using interferon-gamma tests (IGT’s) alone or in combination with a tuberculin skin test, compared with tuberculin skin test alone in •  – adults and children at increased risk of infection • – adults and children who are immunocompromised. • Other aspects of diagnosis and treatment of TB were not covered.

  5. Background: TB • Mycobacterium tuberculosis causes TB. • The body’s immune system is stimulated once the bacteria have been inhaled. • Latent TB –the bacteria lie dormant in the body. • Active TB – symptoms, signs or abnormal chestX-ray.

  6. Background: TB testing • Until recently only Mantoux tests could indicate exposure. They can be inaccurate in certain groups. • IGTs were developed to be more specificby removing false-positive results.

  7. Definitions • Close contacts • Green Book • Hard to reach groups • High-incidence country • High-incidence primary care organisation • Household contacts • ‘Inform and advise’ information • New entrants • Respiratory TB • Standard recommended regimen • Dual strategy

  8. Epidemiology • There are marked differences in the incidence of TB in different parts of England and Wales, with most new cases occurring in cities. • In 2009 in the UK, 9040 cases of TB were reported. This is an increase of 4.2% compared with 2008. • Majority of cases in people who were not born in the UK (73%) and those aged 15–44 years (60%).

  9. Overview of the recommendations • 151 recommendations • 7 key priorities for implementation – identified in 2006 • 18 recommendations were added to the 2006 recommendations – identified by the label ‘[new 2011]’ • 11 recommendations were amended since 2006 – identified by the label ‘[2006, amended 2011]’ • Of the 11 amended recommendations there are ten recommendations where it is believed the amendment may influence clinical practice

  10. Key priorities for implementation There are seven key priority recommendations. Two have been amended and five remain unchanged. The key priorities cover the following areas: • Management of active TB (two recommendations). • Improving adherence (two recommendations). • New entrants screening (one recommendation). • BCG vaccination ( two recommendations).

  11. Diagnosing latent TB:general principles • Offer Mantoux testing to diagnose latent TB in people who are household and non-household contacts. • If Mantoux testing is positive or may be less reliable for example in BCG-vaccinated people, considerIGT. • If Mantoux testing is inconclusive, refer the person to a TB specialist.

  12. Diagnosing latent TB: high-risk countries • Offer a Mantoux test to children aged 5–15 years. If positive, follow with an IGT. • Offer either an IGT alone or a dual strategy in people aged 16–34 years. • For people aged 35 or older, consider risks and benefits of likely subsequent treatment before offering testing. • Offer Mantoux as the initial diagnostic test for latent TB infection in children under 5 years old who have recently arrived from a high-incidence country – if positive refer to TB specialist. High incidence countries are those with more than 40 cases per 100,000 per year

  13. Diagnosing latent TB: outbreaks and people who are immunocompromised • Contacts – outbreak situation • When large numbers may need to be screened offer IGT to people aged 5 and older. • People who are immunocompromised • If latent TB is suspected in children who are immunocompromised, refer to a TB specialist. • For people who are immunocompromised, depending on the degree of immunosuppression, offer IGT alone or an IGT with a Mantoux test.

  14. Diagnosing latent TB: healthcare workers and hard to reach groups • Healthcare workers • Offer a Mantoux test to new NHS employees who are not from high-incidence countries and have not had BCG. • Offer IGT to new NHS employees who have recently arrived from high-incidence countries or have had contact with patients in settings where TB is highly prevalent. • Hard-to-reach populations • Offer a single IGT. High incidence countries are those with more than 40 cases per 100,000 per year

  15. Diagnosing latent TB: contacts under 5 years (1) • Household contacts aged 2–5 years • In children between 2 and 5 years offer Mantoux test as the initial diagnostic test for latent TB infection. • If initial Mantoux test is negative but the child is a contact of sputum-smear-positive disease offer IGT after 6 weeks and repeat Mantoux test. • Neonates who have been in close contact with sputum-smear-positive TB • Who have not received at least 2 weeks anti-TB drug treatment should receive isoniazid, Mantoux test and IGT.

  16. Diagnosing latent TB:contacts under 5 years (2) • The guideline details the assessment and management of children older than 4 weeks but younger than 2 years who have: • not had a BCG • had a BCG • been in close contact with a person with sputum-smear-positive TB.

  17. Costs and savings • Implementing this update is unlikely to result in a significant change in resource use in the NHS. However, recommendations in the following areas may result in additional costs or savings depending on local circumstances: • Offer IGT or dual strategy to people aged 16–35 who are recent arrivals from highly prevalent countries (may have local cost implications if dual strategy employed). • Consider single IGT for people aged 5 years and older in an outbreak situation (potential saving if both TST and IGT are currently being used). 2012: Costs and savings assumptions were not reviewed for the second edition of this slide set

  18. Relevant NICE guidance • PH37: Identifying and managing tuberculosis amonghard-to-reach groups was issued in March 2012. • The guidance aims to improve the way tuberculosis among hard-to-reach groups is identified and managed and sets out how commissioners and services can achieve this. Areas covered include: • Commissioning multidisciplinary TB support for hard-to-reach groups- Identifying and managing active TB in prisons or immigration removal centres- Provision of rapid-access TB services

  19. Discussion • How can we ensure our organisation has access to IGTs? • Are our policies for new entrants from high incidence countries concordant with the recommendations in this guideline? If not, how can we update them? • How can we ensure that our staff understand which diagnostic tests should be used for which groups? • Who do we need to update regarding the new advice for neonates children and young people?

  20. NICE Pathway • This NICE Pathway covers: • Commissioning • Preventing the spread of TB • Diagnosing and managing active TB • Identifying and managing TB among hard to reach groups NICE Tuberculosis Pathway

  21. NHS Evidence • Visit NHS Evidence for the best available evidence on tuberculosis diagnosis, treatment and management NHS Evidence Tuberculosis topic page

  22. Find out more • Visit www.nice.org.uk/guidance/CG117 for: • the guideline • the quick reference guide • ‘Understanding NICE guidance’ • costing statement • audit support • baseline assessment tool.

  23. What do you think? • Did the implementation tool you accessed today meet your requirements, and will it help you to put the NICE guidance into practice? • We value your opinion and are looking for ways to improve our tools. Please complete this short evaluation form. • If you are experiencing problems accessing or using this tool, please email implementation@nice.org.uk To open the links on this slide right click over the link and choose ‘open link’

More Related